Eversept Partners, LP Avrobio, Inc. Transaction History

Eversept Partners, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.75 - $1.33 $221,526 - $392,840	-295,369 Closed	0 $0
Q1 2022 Nov 08, 2023	BUY	$1.29 - $4.04 $381,026 - $1.19 Million	295,369 New	295,369 $389,000
Q1 2022 May 16, 2022	SELL	$1.29 - $4.04 $12,409 - $38,864	-9,620 Reduced 3.15%	295,369 $390,000
Q4 2021 Nov 08, 2023	SELL	$3.45 - $6.05 $187,993 - $329,670	-54,491 Reduced 15.16%	304,989 $1.17 Million
Q4 2021 Feb 14, 2022	SELL	$3.45 - $6.05 $187,993 - $329,670	-54,491 Reduced 15.16%	304,989 $1.17 Million
Q3 2021 Nov 08, 2023	BUY	$5.53 - $9.28 $1.99 Million - $3.34 Million	359,480 New	359,480 $2.01 Million
Q3 2021 Nov 15, 2021	BUY	$5.53 - $9.28 $1.99 Million - $3.34 Million	359,480 New	359,480 $2.01 Million

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.